Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome

INTRODUCTION: In randomly assigned studies with EGFR TKI only a minor proportion of patients with NSCLC have genetically profiled biopsies. Guidelines provide evidence to perform EGFR and KRAS mutation analysis in non-squamous NSCLC. We explored tumor biopsy quality offered for mutation testing, different mutations distribution, and outcome with EGFR TKI. PATIENT AND METHODS: Clinical data from 8 regional hospitals were studied for patient and tumor characteristics, treatment and overall survival. Biopsies sent to the central laboratory were evaluated for DNA quality and subsequently analyzed... Mehr ...

Verfasser: Kerner, Gerald S. M. A.
Schuuring, Ed
Sietsma, Johanna
Hiltermann, Thijo J. N.
Pieterman, Remge M.
de Leede, Gerard P. J.
van Putten, John W. G.
Liesker, Jeroen
Renkema, Tineke E. J.
van Hengel, Peter
Platteel, Inge
Timens, Wim
Groen, Harry J. M.
Dokumenttyp: Artikel
Erscheinungsdatum: 2013
Reihe/Periodikum: Kerner , G S M A , Schuuring , E , Sietsma , J , Hiltermann , T J N , Pieterman , R M , de Leede , G P J , van Putten , J W G , Liesker , J , Renkema , T E J , van Hengel , P , Platteel , I , Timens , W , Groen , H J M & CTMM Air Force Consortium 2013 , ' Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome ' , PLoS ONE , vol. 8 , no. 7 , e70346 . https://doi.org/10.1371/journal.pone.0070346
Schlagwörter: Antineoplastic Agents / Biopsy / Carcinoma / Non-Small-Cell Lung / Humans / Lung Neoplasms / Mutation / Neoplasm Metastasis / Neoplasm Staging / Netherlands / Patient Outcome Assessment / Prognosis / Protein Kinase Inhibitors / Receptor / Epidermal Growth Factor / Treatment Outcome / ras Proteins
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26670544
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/11370/35c7ff79-f406-42f0-ab14-0c1fbfd71184